The percentage of potential T-cell responses achieved in each category revealed a nonsignificant trend toward higher responses among ACPA+ RA patients to the created peptides (33%) than to no change (17%; P = 0.2918) and destroyed (13%; P = 0.1692) peptide groups, in addition to significantly more frequent responses among ACPA+ RA patients to the created peptides (33%) than observed for the controls by χ2 test (2.5%; P = 0.0002; Fig. 6b). The gene discussed is PRTN3; the disease is rheumatoid arthritis.